Perampanel, a selective, non‐competitive, AMPA receptor antagonist, is approved in >50 countries for adjunctive treatment of partial‐onset seizures (POS), with or without secondarily generalized seizures, and for primary generalized tonic‐clonic seizures in patients with epilepsy aged ≥12 years. In the United States, perampanel was recently approved for monotherapy use for POS in patients with epilepsy aged ≥12 years. Approvals for POS were based on three randomized, double‐blind, placebo‐controlled phase III studies (Studies 304, 305, and 306), in which adjunctive perampanel 4‐12 mg/d reduced the frequency of POS compared with placebo.Study 335 (NCT01618695), a randomized, double‐blind, placebo‐controlled phase III trial, evaluated the efficacy, safety, and tolerability of adjunctive perampanel (4‐12 mg/d) in an Asia‐Pacific population with refractory POS. This study provided an opportunity to explore regional similarities and differences compared with the predominantly Caucasian populations who had participated in Studies 304, 305, and 306. Efficacy and safety outcomes from Study 335 were similar to the previous phase III studies, supporting a consistent profile for perampanel across different populations with POS.In Studies 304 and 305, perampanel 12 mg/d did not appear to offer additional efficacy benefits compared with 8 mg/d, despite the log‐linear relationship between perampanel exposure and efficacy. Therefore, Study 335 explored the perampanel dose‐response relationship
Acta Neurologica Scandinavica – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera